Challenged to remove matrix interferences while dealing with the evolving complexity of biotherapeutics? In this webinar we will detail how to overcome background interference challenges, which might otherwise limit assay capabilities, through exploring and examining multiple case studies. These include the elimination of endogenous interference in allopurinol assays and the resolution of matrix interference, as well as the simplification of sample preparation in rituximab quantitation.
You will learn how to:
- How to eliminate endogenous/exogenous isobaric interference (e.g., isomers)
- Methods for the reduction of chemical/background noise to improve S/N ratio and promote achievable LLOQs
- What can be done to simplify exhaustive sample preparation and complex chromatographic separations
- How to minimize time required for method development
- Key advantages of SelexION+® technology
Who may this interest?
- CROs, pharma and biotech organizations focused on enhancing selectivity for LC–MS quantitative bioanalysis
- Mass spectrometrists and bioanalytical scientists engaged in assay development
- Academics and students interested in the applications of ion mobility spectrometry
Dr. Mingluan Chen joined Altasciences (Laval, Canada) as Senior Scientist, Method Development after completing his PhD in micro-scale LC-MS for small molecules at Wuhan University (Hubei, China) in 2013. Over the past four years, Dr. Chen has been focusing on Innovator molecules as part of both preclinical and clinical drug development programs and has developed over 50 de novo LC-MS assays. He has also authored 20 peer-reviewed articles and has contributed to many scientific posters and presentations. Dr. Chen is currently focusing on the implementation of new technologies in bioanalysis alongside Altasciences’ Innovator team.